一种安全有效的 BCG 载体疫苗，用于预防由人类呼吸道合胞病毒引起的疾病。
A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.
机构信息
a Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas , Pontificia Universidad Católica de Chile , Santiago , Chile.
b Departamento de Endocrinología, Facultad de Medicina , Pontificia Universidad Católica de Chile , Santiago , Chile.
出版信息
Hum Vaccin Immunother. 2017 Sep 2;13(9):2092-2097. doi: 10.1080/21645515.2017.1334026. Epub 2017 Jun 9.
Abstract
The human Respiratory Syncytial Virus (hRSV) causes lower respiratory tract infections including pneumonia and bronchiolitis. Such infections also cause a large number of hospitalizations and affects mainly newborns, young children and the elderly worldwide. Symptoms associated with hRSV infection are due to an exacerbated immune response characterized by low levels of IFN-γ, recruitment of neutrophils and eosinophils to the site of infection and lung damage. Although hRSV is a major health problem, no vaccines are currently available. Different immunization approaches have been developed to achieve a vaccine that activates the immune system, without triggering an unbalanced inflammation. These approaches include live attenuated vaccine, DNA or proteins technologies, and the use of vectors to express proteins of the virus. In this review, we discuss the host immune response to hRSV and the immunological mechanisms underlying an effective and safe BCG vectored vaccine against hRSV.
摘要
人类呼吸道合胞病毒（hRSV）可引起下呼吸道感染，包括肺炎和细支气管炎。此类感染还会导致大量住院治疗，并且主要影响全球的新生儿、幼儿和老年人。与 hRSV 感染相关的症状是由于免疫反应加剧所致，其特征是 IFN-γ 水平降低、中性粒细胞和嗜酸性粒细胞募集到感染部位和肺部损伤。尽管 hRSV 是一个主要的健康问题，但目前尚无可用的疫苗。已经开发了不同的免疫接种方法来实现一种能够激活免疫系统而不引发失衡炎症的疫苗。这些方法包括减毒活疫苗、DNA 或蛋白质技术，以及使用载体来表达病毒蛋白。在这篇综述中，我们讨论了宿主对 hRSV 的免疫反应以及基于卡介苗载体疫苗对 hRSV 有效和安全的免疫机制。
相似文献
1
A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.一种安全有效的 BCG 载体疫苗，用于预防由人类呼吸道合胞病毒引起的疾病。
Hum Vaccin Immunother. 2017 Sep 2;13(9):2092-2097. doi: 10.1080/21645515.2017.1334026. Epub 2017 Jun 9.
2
A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.单剂量低剂量的cGMP重组卡介苗可引发针对人类呼吸道合胞病毒感染的保护性T细胞免疫，并预防小鼠的肺部病变。
Vaccine. 2017 Feb 1;35(5):757-766. doi: 10.1016/j.vaccine.2016.12.048. Epub 2017 Jan 5.
3
Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.高龄人群针对人呼吸道合胞病毒感染的疫苗接种免疫反应受损。
J Virol. 2014 Sep 1;88(17):9744-50. doi: 10.1128/JVI.01101-14. Epub 2014 Jun 11.
4
Human Respiratory Syncytial Virus: Role of Innate Immunity in Clearance and Disease Progression.人呼吸道合胞病毒：固有免疫在清除病毒及疾病进展中的作用
Viral Immunol. 2016 Jan-Feb;29(1):11-26. doi: 10.1089/vim.2015.0098. Epub 2015 Dec 17.
5
New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.有助于开发有效疫苗和疗法以减少人呼吸道合胞病毒所致病理的新见解。
Int J Mol Sci. 2017 Aug 11;18(8):1753. doi: 10.3390/ijms18081753.
6
A Recombinant BCG Vaccine Is Safe and Immunogenic in Neonatal Calves and Reduces the Clinical Disease Caused by the Respiratory Syncytial Virus.一种重组卡介苗疫苗在新生小牛中安全且具有免疫原性，并可降低呼吸道合胞病毒引起的临床疾病。
Front Immunol. 2021 Apr 26;12:664212. doi: 10.3389/fimmu.2021.664212. eCollection 2021.
7
Immunopathology of RSV infection: prospects for developing vaccines without this complication.呼吸道合胞病毒感染的免疫病理学：开发无此并发症疫苗的前景。
Rev Med Virol. 2007 Jan-Feb;17(1):5-34. doi: 10.1002/rmv.518.
8
Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design.呼吸道合胞病毒所致肺炎的免疫学特征——对疫苗设计的启示
Int J Mol Sci. 2017 Mar 4;18(3):556. doi: 10.3390/ijms18030556.
9
Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.病毒载体疫苗对人类和牛呼吸道合胞病毒感染的疗效。
Sci Transl Med. 2015 Aug 12;7(300):300ra127. doi: 10.1126/scitranslmed.aac5757.
10
Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.新型人呼吸道合胞病毒重组DNA疫苗候选物：免疫原性和保护效率的临床前评估
Hum Vaccin Immunother. 2017 Jul 3;13(7):1586-1597. doi: 10.1080/21645515.2017.1295190. Epub 2017 Mar 8.
引用本文的文献
1
A recombinant BCG with surface-displayed antigen induces humoral and cellular immune responses.一种表面展示抗原的重组卡介苗可诱导体液免疫和细胞免疫反应。
Sci Rep. 2025 May 16;15(1):17099. doi: 10.1038/s41598-025-00553-x.
2
Beyond Tuberculosis: The Surprising Immunological Benefits of the Bacillus Calmette-Guérin (BCG) Vaccine in Infectious, Auto-Immune, and Inflammatory Diseases.超越结核病：卡介苗（BCG）疫苗在感染性、自身免疫性和炎症性疾病中令人惊讶的免疫学益处
Pathogens. 2025 Feb 15;14(2):196. doi: 10.3390/pathogens14020196.
3
Engineering a dual vaccine against COVID-19 and tuberculosis.工程双疫苗以预防 COVID-19 和结核病。
Front Cell Infect Microbiol. 2023 Oct 26;13:1273019. doi: 10.3389/fcimb.2023.1273019. eCollection 2023.
4
Multidimensional futuristic approaches to address the pandemics beyond COVID-19.应对新冠疫情之外的大流行病的多维未来主义方法。
Heliyon. 2023 Jun;9(6):e17148. doi: 10.1016/j.heliyon.2023.e17148. Epub 2023 Jun 11.
5
Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19.BCG 对 COVID-19 的特异性和非特异性免疫作用及其保护作用的研究进展。
Front Immunol. 2023 Jan 31;14:1118378. doi: 10.3389/fimmu.2023.1118378. eCollection 2023.
6
Current GMP standards for the production of vaccines and antibodies: An overview.现行疫苗和抗体生产的 GMP 标准：概述。
Front Public Health. 2022 Nov 3;10:1021905. doi: 10.3389/fpubh.2022.1021905. eCollection 2022.
7
A Recombinant BCG Vaccine Is Safe and Immunogenic in Neonatal Calves and Reduces the Clinical Disease Caused by the Respiratory Syncytial Virus.一种重组卡介苗疫苗在新生小牛中安全且具有免疫原性，并可降低呼吸道合胞病毒引起的临床疾病。
Front Immunol. 2021 Apr 26;12:664212. doi: 10.3389/fimmu.2021.664212. eCollection 2021.
8
The BCG Vaccine for COVID-19: First Verdict and Future Directions.《COVID-19 用卡介苗疫苗：初步结论和未来方向》
Front Immunol. 2021 Mar 8;12:632478. doi: 10.3389/fimmu.2021.632478. eCollection 2021.
9
The Future of Respiratory Syncytial Virus Disease Prevention and Treatment.呼吸道合胞病毒疾病防治的未来
Infect Dis Ther. 2021 Mar;10(Suppl 1):47-60. doi: 10.1007/s40121-020-00383-6. Epub 2021 Mar 3.
10
BCG vaccination induced protection from COVID-19.BCG 疫苗接种可预防 COVID-19。
Indian J Tuberc. 2021 Jan;68(1):119-124. doi: 10.1016/j.ijtb.2020.08.004. Epub 2020 Aug 7.
本文引用的文献
1
Preclinical development of BCG.HIVA, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.携带整合表达载体的卡介苗.HIVA用于儿童HIV-结核病疫苗的临床前开发。增强稳定性和特异性HIV-1 T细胞免疫。
Hum Vaccin Immunother. 2017 Aug 3;13(8):1798-1810. doi: 10.1080/21645515.2017.1316911. Epub 2017 Apr 20.
2
A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.单剂量低剂量的cGMP重组卡介苗可引发针对人类呼吸道合胞病毒感染的保护性T细胞免疫，并预防小鼠的肺部病变。
Vaccine. 2017 Feb 1;35(5):757-766. doi: 10.1016/j.vaccine.2016.12.048. Epub 2017 Jan 5.
3
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.MEDI8897（一种半衰期延长的呼吸道合胞病毒前融合F靶向单克隆抗体）在健康成人中的安全性、耐受性和药代动力学。
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01714-16. Print 2017 Mar.
4
A Model to Explain How the Bacille Calmette Guérin (BCG) Vaccine Drives Interleukin-12 Production in Neonates.一种解释卡介苗（BCG）疫苗如何驱动新生儿白细胞介素-12产生的模型。
PLoS One. 2016 Aug 29;11(8):e0162148. doi: 10.1371/journal.pone.0162148. eCollection 2016.
5
Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.联合病毒样颗粒和编码融合蛋白的DNA疫苗接种棉鼠可诱导对呼吸道合胞病毒的保护作用，且不会引起疫苗增强性疾病。
Virology. 2016 Jul;494:215-24. doi: 10.1016/j.virol.2016.04.014. Epub 2016 Apr 26.
6
Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.由F糖蛋白的融合后和融合前构象组成的新型呼吸道合胞病毒样颗粒疫苗。
Clin Vaccine Immunol. 2016 Jun 6;23(6):451-9. doi: 10.1128/CVI.00720-15. Print 2016 Jun.
7
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.一种基于融合机制结构分析的高度稳定的预融合呼吸道合胞病毒F疫苗。
Nat Commun. 2015 Sep 3;6:8143. doi: 10.1038/ncomms9143.
8
Elevated IL-3 and IL-12p40 levels in the lower airway of infants with RSV-induced bronchiolitis correlate with recurrent wheezing.呼吸道合胞病毒（RSV）诱发的细支气管炎婴儿下呼吸道中白细胞介素-3（IL-3）和白细胞介素-12p40水平升高与反复喘息相关。
Cytokine. 2015 Dec;76(2):417-423. doi: 10.1016/j.cyto.2015.07.017. Epub 2015 Aug 20.
9
IL-33 Receptor (ST2) Signalling is Important for Regulation of Th2-Mediated Airway Inflammation in a Murine Model of Acute Respiratory Syncytial Virus Infection.白细胞介素-33受体（ST2）信号传导对于急性呼吸道合胞病毒感染小鼠模型中Th2介导的气道炎症调节至关重要。
Scand J Immunol. 2015 Jun;81(6):494-501. doi: 10.1111/sji.12284.
10
Galectin-9 ameliorates respiratory syncytial virus-induced pulmonary immunopathology through regulating the balance between Th17 and regulatory T cells.半乳糖凝集素-9通过调节辅助性T细胞17和调节性T细胞之间的平衡来改善呼吸道合胞病毒诱导的肺部免疫病理学。
Virus Res. 2015 Jan 2;195:162-71. doi: 10.1016/j.virusres.2014.10.011. Epub 2014 Oct 16.
Zotero 插件